This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Thomas T. Provost, MD; Norman Talal, MD; John B. Harley, MD, PhD; Morris Reichlin, MD; Elaine Alexander, MD, PhD

Arch Dermatol. 1988;124(1):63-71.

Abstract
• Ten Ro(SS-A) antibody-positive patients with Sjögren's syndrome and lupus erythematosus are described. These patients have a disease process characterized by the frequent appearance of annular polycyclic lupus lesions of subacute cutaneous lupus erythematosus (SCLE), as well as neurologic and pulmonary disease. The Ro(SS-A) antibody-positive patients may have Sjögren's syndrome for many years and then suddenly develop lupus erythematosus, and vice versa. These studies demonstrate that the patient with Ro(SS-A) antibody may exhibit a dynamic clinical disease expression over time and that there is a closer pathologic relationship between Sjögren's syndrome and SCLE in these patients with Ro(SS-A)-antibody than has previously been appreciated. Furthermore, Ro(SS-A)-positive patients with Sjögren's syndrome and lupus erythematosus appear to have a much more guarded prognosis than those Ro(SS-A)-positive lupus patients described under the classifications of antinuclear antibody-negative lupus erythematosus and SCLE.

(Arch Dermatol 1988;124:63-71)

Author Affiliations
From the Department of Dermatology (Dr Provost) and Division of Rheumatology (Dr Alexander), Johns Hopkins Medical Institutions, Baltimore; Division of Clinical Immunology, University of Texas Health Science Center at San Antonio (Dr Talal); Department of Medicine (Dr Harley) and Immunology Section (Dr Reichlin), University of Oklahoma College of Medicine, Oklahoma City; Arthritis and Immunology Program, Oklahoma Medical Research Foundation, (Dr Provost); Veterans Administration Medical Center, Oklahoma City (Dr Harley); and Arthritis and Immunology Laboratory, Oklahoma Medical Research Foundation, Oklahoma City (Dr Harley).

Footnotes
Accepted for publication Sept 4, 1987.

Reprint requests to Department of Dermatology, Johns Hopkins Medical Institution, 600 N Wolfe St, Baltimore, MD 21205 (Dr Provost).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus
Egerer et al.
Lupus 2000;9:614-621.
ABSTRACT  

The spectrum of cutaneous manifestations in lupus erythematosus--the Italian experience
Cardinali et al.
Lupus 2000;9:417-423.
ABSTRACT  

Anti-{alpha}-Fodrin Antibodies in Sjogren Syndrome and Lupus Erythematosus
Watanabe et al.
Arch Dermatol 1999;135:535-539.
ABSTRACT | FULL TEXT  

Anti-Ro(SS-A) antibody positive Sjogren's/lupus erythematosus overlap syndrome
Provost et al.
Lupus 1997;6:105-111.
ABSTRACT  

Cutaneous diseases in adults associated with Anti-Ro/SS-A autoantibody production
McCauliffe
Lupus 1997;6:158-166.
 

Similar Ro/SS-A Autoantibody Epitope and Titer Responses in Annular Erythema of Sjogren's Syndrome and Subacute Cutaneous Lupus Erythematosus
McCauliffe et al.
Arch Dermatol 1996;132:528-531.
ABSTRACT  

The Autoantibody Response to Ro/SSA in Cutaneous Lupus Erythematosus
Lee et al.
Arch Dermatol 1994;130:1262-1268.
ABSTRACT  

Anti-Ro (SSA) and Anti-La (SSB) Antibodies in Lupus Erythematosus and in Sjogren's Syndrome
Lee
Arch Dermatol 1988;124:61-62.
ABSTRACT